Want to see DMRA full AI Analyst Report?
DMRA Stock Chart & Stats
$28.82
$0.76(2.64%)
At close: 4:00 PM EDT
$28.82
$0.76(2.64%)
Day’s Range― - ―
52-Week Range$2.45 - $38.33
Previous CloseN/A
Volume313.81K
Average Volume (3M)793.64K
Market Cap
$1.78B
Enterprise Value$488.85
Total Cash (Recent Filing)$532.90M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 05, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-121.91
Shares Outstanding61,553,192
10 Day Avg. Volume469,145
30 Day Avg. Volume793,645
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-4.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.43Price Target Upside54.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseVery low debt and a sizable equity base materially reduce solvency risk for this pre-revenue biotech. That structural balance-sheet flexibility allows management to fund R&D, pursue partnerships or acquisitions, and time capital raises without immediate liquidity pressure.
Improving Cash Outflow TrendA meaningful reduction in annual cash burn suggests operational discipline or milestone-driven cost control. If sustained, this lowers near-term funding needs, extends runway, and improves chances of advancing programs to value-inflection points before needing dilutive financing.
Leadership Continuity And GovernancePromoting an experienced internal finance executive provides continuity during post-acquisition integration and reporting. Combined with recent director elections and auditor ratification, this strengthens financial stewardship and governance credibility over the coming quarters.
Bears Say
No RevenueBeing pre-revenue means all value depends on successful R&D, regulatory outcomes, or partner deals. Lack of commercial cash flow forces persistent external financing, raising execution risk and making long-term sustainability contingent on scientific and regulatory milestones.
Large, Volatile Net LossesA sharp jump and volatility in net losses increases dilution risk and can signal heavy one-time charges or rapid program spending. Such variability complicates planning, pressures governance around capital allocation, and raises the bar for fundraising without significant value inflection.
Negative Cash Generation; Funding DependencePersistent negative operating and free cash flow forces repeated capital raises and heightens exposure to market conditions. Reliance on external funding is a recurring structural vulnerability that can constrain program execution timing and dilute existing shareholders.
Damora Therapeutics News
DMRA FAQ
What was Damora Therapeutics, Inc.’s price range in the past 12 months?
Damora Therapeutics, Inc. lowest stock price was $2.45 and its highest was $38.33 in the past 12 months.
What is Damora Therapeutics, Inc.’s market cap?
Damora Therapeutics, Inc.’s market cap is $1.78B.
When is Damora Therapeutics, Inc.’s upcoming earnings report date?
Damora Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 2 days.
How were Damora Therapeutics, Inc.’s earnings last quarter?
Damora Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.232.
Is Damora Therapeutics, Inc. overvalued?
According to Wall Street analysts Damora Therapeutics, Inc.’s price is currently Undervalued.
Does Damora Therapeutics, Inc. pay dividends?
Damora Therapeutics, Inc. does not currently pay dividends.
What is Damora Therapeutics, Inc.’s EPS estimate?
Damora Therapeutics, Inc.’s EPS estimate is -0.41.
How many shares outstanding does Damora Therapeutics, Inc. have?
Damora Therapeutics, Inc. has 61,553,192 shares outstanding.
What happened to Damora Therapeutics, Inc.’s price movement after its last earnings report?
Damora Therapeutics, Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went up 4.634%.
Which hedge fund is a major shareholder of Damora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Damora Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.43 (54.16% Upside)
$44.43 (54.16% Upside)
Blogger Sentiment
Bullish
DMRA Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
685.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3384.82%
Trailing 12-Months
Company Description
Damora Therapeutics, Inc.
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
DMRA Stock 12 Month Forecast
Average Price Target
$44.43
▲(54.16% Upside)
Technical Analysis
Ownership Overview
15.94% Insiders
10.72% Mutual Funds
― Other Institutional Investors
67.45% Public Companies and
Individual Investors